Katarzyna Ziółkowska

Katarzyna Ziółkowska

Auto-generated profile, based on publicly available information

Katarzyna Ziółkowska

Department of Laboratory Diagnostics, Poznan University of Medical Sciences, Poznan, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Ginekologia Polska
Verified
Journal Article
Open access
JKJakub Kornacki
Jakub Kornacki
KZKatarzyna Ziółkowska
Katarzyna Ziółkowska
NINatalia Ignaszak
Natalia Ignaszak
JSJana Skrzypczak
Jana Skrzypczak
The aim of the study was a long-term follow-up of children with prenatally found increased nuchal translucency (NT) and normal karyotype. The study was conducted among 147 pregnant women who underwent amniocentesis due to increased fetal NT with or without other structural anomalies in the fetus. The final analysis concerned children with prenatally found increased NT and normal karyotype who were at least 2 years of age. A questionnaire was sent to all patients who underwent amniocentesis in order to assess the development of the children. Normal karyotype was found in 101 (68.7%) fetuses with increased NT Complete information on the outcome of pregnancy and further development of the children was submitted by 70 patients (69.3%). An abnormal outcome of pregnancy congenital structural anomalies and abnormal development was found finally in 17.1% of the children. In case of normal result of the second-trimester fetal ultrasound scan, normal further development was found in 93% of the children. 1. Further development of the children with prenatally found increased NT and normal karyotype is usually normal. 2. The degree of NT increase and the result of the second-trimester fetal anatomy scan seem to play the key role in the prognosis of further, postnatal outcome of the fetuses with increased NT 3. Normal karyotype in fetuses with increased NT does not exclude the possibility of an existing genetic syndrome.

20 September 2026 in Cardiovascular Toxicology
Verified
Journal Article
Open access
PDF file
PSPaulina Szubińska-Bałaban
Paulina Szubińska-Bałaban
AKAneta Klotzka
Aneta Klotzka
KZKatarzyna Ziółkowska
Katarzyna Ziółkowska
PMPatrycja Marciniak-Stępak
Patrycja Marciniak-Stępak
JNJulia Niedzielska
Julia Niedzielska
EBEwelina Bukowska-Olech
Ewelina Bukowska-Olech
Cancer therapy-related cardiovascular toxicity (CTR-CVT) is an umbrella term for myocardial, vascular, electrical, and inflammatory complications of cytotoxic, targeted, immune, and radiation-based therapies. Cancer therapy-related cardiac dysfunction (CTRCD) is used here more narrowly for treatment-related myocardial dysfunction, typically identified by changes in left ventricular ejection fraction, global longitudinal strain, and/or cardiac biomarkers. The pathophysiology of CTR-CVT is multifactorial, but the implicated pathways should not be interpreted as equally causal. The dominant initiating mechanism is therapy-specific - anthracycline injury is best supported by topoisomerase IIβ (TOP2B)-mediated DNA damage with secondary mitochondrial and redox injury; HER2-directed toxicity by disruption of NRG1-ERBB2/ERBB4 survival signalling; fluoropyrimidine toxicity by coronary vasomotor dysfunction; VEGF-pathway inhibition by endothelial dysfunction and hypertension; immune checkpoint inhibitor toxicity by loss of immune tolerance; and radiotherapy injury by endothelial and microvascular damage with progressive fibrosis. Mitochondrial dysfunction, oxidative stress, inflammation, calcium dysregulation, apoptosis, and ferroptosis frequently act as downstream or amplifying pathways, although the clinical relevance of several regulated cell-death mechanisms remains incompletely established. Genetic susceptibility may further modify risk, but the strength of evidence differs among reported loci. Replicated pharmacogenetic associations, rare variants in established cardiomyopathy genes, and preliminary candidate-gene findings should therefore be considered separately. Most available studies remain limited by small cohorts, heterogeneous phenotyping, ancestry imbalance, and incomplete external replication. This review critically evaluates the hierarchy and strength of mechanistic and genetic evidence and discusses the extent to which these findings can currently inform risk stratification, surveillance, prevention, and treatment in precision cardio-oncology. Graphical Abstract